These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
566 related articles for article (PubMed ID: 31834000)
1. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Tenorio AR; Pappa KA; Wynne B; Gartland M; Aboud M; van Wyk J; Smith KY J Acquir Immune Defic Syndr; 2020 Mar; 83(3):310-318. PubMed ID: 31834000 [TBL] [Abstract][Full Text] [Related]
2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K; Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123 [TBL] [Abstract][Full Text] [Related]
3. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595 [TBL] [Abstract][Full Text] [Related]
4. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. Ait-Khaled M; Sierra Madero J; Estrada V; Gulminetti R; Hagins D; Tsai HC; Man C; Sievers J; Grove R; Zolopa A; Wynne B; van Wyk J HIV Res Clin Pract; 2021 Dec; 23(1):9-14. PubMed ID: 34913844 [No Abstract] [Full Text] [Related]
5. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489 [TBL] [Abstract][Full Text] [Related]
6. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D D2EFT Study Group Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744 [TBL] [Abstract][Full Text] [Related]
7. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; van Wyk J; Wynne B AIDS; 2022 Jan; 36(1):39-48. PubMed ID: 34534138 [TBL] [Abstract][Full Text] [Related]
8. Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Underwood M; Urbaityte R; Wang R; Horton J; Oyee J; Wynne B; Fox D; Jones B; Man C; Sievers J Viruses; 2024 Mar; 16(3):. PubMed ID: 38543770 [TBL] [Abstract][Full Text] [Related]
9. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240 [TBL] [Abstract][Full Text] [Related]
10. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270 [TBL] [Abstract][Full Text] [Related]
11. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J; Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487 [TBL] [Abstract][Full Text] [Related]
14. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Greig SL; Deeks ED Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454 [TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY; Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158 [TBL] [Abstract][Full Text] [Related]
16. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection. Santevecchi BA; Miller S; Childs-Kean LM Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480 [TBL] [Abstract][Full Text] [Related]
17. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610 [TBL] [Abstract][Full Text] [Related]
18. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Taiwo BO; Zheng L; Stefanescu A; Nyaku A; Bezins B; Wallis CL; Godfrey C; Sax PE; Acosta E; Haas D; Smith KY; Sha B; Van Dam C; Gulick RM Clin Infect Dis; 2018 May; 66(11):1689-1697. PubMed ID: 29253097 [TBL] [Abstract][Full Text] [Related]
19. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Scott LJ Drugs; 2020 Jan; 80(1):61-72. PubMed ID: 31865558 [TBL] [Abstract][Full Text] [Related]
20. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]